Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Trial in progress: Phase II Study of (early) combination salvage therapy with venetoclax and intensified decitabine in relapsed/refractory AML (VenSwitch)

Lucas Mix, Jan Christian Schroeder, Osama Ahmad, Franziska Ginsberg, Andreas Riedel, David Soekler-Sanchez, Lennart Harland, Rebecca Froehlich, Jonas Schmidt, Nicolae Anghel, Peter Martus, Wichard Vogel, Britta Besemer, Wolfgang Bethge, Claudia Lengerke

Blood (2025) 146 (Supplement 1): 8253.

https://doi.org/10.1182/blood-2025-8253

Published: 2025

Journal Articles

CD19/CD22 CAR-T cells in adult patients with relapsed/refractory B-cell malignancies

Laurent Phely, Stefan Hug, Luca Hensen, Elena Mirovic, Christoph Faul, Wichard Vogel, Claudia Lengerke, Wolfgang Bethge

Blood (2025) 146 (Supplement 1): 4142.

https://doi.org/10.1182/blood-2025-4142

Published: 2025

Journal Articles

Trial in progress: Safety and feasibility of a venetoclax-augmented treosulfan-based reduced intensity conditioning before allogeneic stem cell transplantation in AML, MDS/AML and higher risk MDS (VeStAL)

Lucas Mix, Wichard Vogel, Britta Besemer, Peter Martus, Claudia Lengerke, Wolfgang Bethge, Christoph Faul

Blood (2025) 146 (Supplement 1): 6001.

https://doi.org/10.1182/blood-2025-6001

Published: 2025

Journal Articles

Allogeneic Hematopoietic Cell Transplant Recipients Carrying DNMT3A and ASXL1 Mutations More Frequently Develop Severe Graft Versus Host Disease and Arterial Hypertension

Alisha Weiss-Haug, Reka A Haraszti, Britta Merz, Kristina Reuss, Christoph Faul, Wolfgang Andreas Bethge, Frederike Schwartz, Wichard Vogel, Claudia Lengerke

Blood (2023) 142 (Supplement 1): 3564.

https://doi.org/10.1182/blood-2023-188752

Published: 2023

Journal Articles

Prospective Evaluation of Patient-Reported Outcome up to 10 Years after Allogeneic Stem Cell Transplantation Using FACT-G/BMT and EORTC-QLQ30 Questionnaires

Sina Alexandra Beer, Johanna Blaettel, Kristina Reuss, Jan Christian Schröder, Wichard Vogel, Christoph Faul, Wolfgang Andreas Bethge, Claudia Lengerke

Blood (2023) 142 (Supplement 1): 2208.

https://doi.org/10.1182/blood-2023-188833

Published: 2023

Journal Articles

Addition of Plerixafor Overcomes Poor Mobilization in Autologous and Allogeneic Stem Cell Grafts and Leads to Efficient and Sustained Engraftment

Sebastian Haen, MD, Irmtraud Schober-Melms, Michael Schumm, DVM, Joerg Henes, Robert Möhle, MD, Wolfgang Bethge, MD, Lothar Kanz, Wichard Vogel

Blood (2017) 130 (Supplement 1): 5457.

https://doi.org/10.1182/blood.V130.Suppl_1.5457.5457

Published: 2017

Journal Articles

Disease and Therapy Associated Complications of the Central Nervous System after Allogeneic Hematopoietic Cell Transplantation - a Significant Proportion of Patients Will Suffer from Permanent Damage

Sebastian P. Haen, MD, Manfred Zierhut, MD, Nora Mirza, PhD, Christoph M. Simon, MD, Andreas Korn, MD, Christoph Faul, MD, Wichard Vogel, MD, Hans-Georg Rammensee, PhD, Lothar Kanz, MD, Wolfgang Bethge, MD

Blood (2016) 128 (22): 4620.

https://doi.org/10.1182/blood.V128.22.4620.4620

Published: 2016

Journal Articles

Epigenetic Upregulation of the O-Linked Beta-N-Acetylglucosamine Transferase (OGT) in Response to Dronabinol Results in Antileukemic Efficacy In Vivo

Kerstin Maria Kampa-Schittenhelm, MD, Hans-Joerg Buehring, Michael Bonin, Wichard Vogel, MD, Lothar Kanz, Prof. Dr. MD, Thomas Haverkamp, Marcus M Schittenhelm, MD

Blood (2015) 126 (23): 2437.

https://doi.org/10.1182/blood.V126.23.2437.2437

Published: 2015

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome: Impact of Age and Conditioning

Jörg Schmohl, MD, Spanier Lena, Christiane Dorn, MD, Christoph Faul, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang Bethge, MD

Blood (2014) 124 (21): 5939.

https://doi.org/10.1182/blood.V124.21.5939.5939

Published: 2014

Journal Articles

Haploidentical Transplantation As Salvage Therapy For Disease Relapse After Allogeneic Hematopoietic Cell Transplantation

Christiane Dorn, MD, Sebastian P. Haen, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang A Bethge, MD

Blood (2013) 122 (21): 2084.

https://doi.org/10.1182/blood.V122.21.2084.2084

Published: 2013

Journal Articles

Allogeneic Hematopoietic Cell Transplantation For Patients With Primary and Secondary Myelofibrosis: Report Of a Single Center Experience

Christiane Dorn, MD, Sebastian P. Haen, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang A Bethge, MD

Blood (2013) 122 (21): 4538.

https://doi.org/10.1182/blood.V122.21.4538.4538

Published: 2013

Journal Articles

Haploidentical TCRab Depleted Hematopoietic Cell Transplantation Leads To Rapid Immune Reconstitution and Promising Clinical Outcome In Adults

Sebastian P. Haen, MD, Michael Schumm, DVM, Wichard Vogel, MD, Christoph Faul, MD, Rupert Handgretinger, Lothar Kanz, MD, Wolfgang A. Bethge, MD

Blood (2013) 122 (21): 5475.

https://doi.org/10.1182/blood.V122.21.5475.5475

Published: 2013

Journal Articles

Central Nervous System Complications After Allogeneic Hematopoietic Cell Transplantation – Treatment Related Morbidity, Toxicity, Graft Versus Host Disease Or New Autoimmunity

Christoph Simon, Nora Mirza, Wolfgang A. Bethge, MD, Wichard Vogel, MD, Christoph Faul, MD, Hans-Georg Rammensee, Lothar Kanz, MD, Sebastian P. Haen, MD

Blood (2013) 122 (21): 2069.

https://doi.org/10.1182/blood.V122.21.2069.2069

Published: 2013

Journal Articles

Delayed Immune Reconstitution After Allogeneic Hematopoietic Cell Transplantation with Yttrium-90 Ibritumomab Tiuxetan-Based Reduced-Intensity Conditioning

Dominik Schneidawind, MD, Sebastian Jendryssek, Birgit Federmann, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang A Bethge, MD

Blood (2012) 120 (21): 4482.

https://doi.org/10.1182/blood.V120.21.4482.4482

Published: 2012

Journal Articles

Reduced-Intensity Conditioning with Fludarabine and Busulfan: Age Has No Negative Impact On Survival

Dominik Schneidawind, MD, Birgit Federmann, MD, Andrea Helwig, Wichard Vogel, MD, Christoph Faul, MD, Lothar Kanz, MD, Wolfgang A Bethge, MD

Blood (2012) 120 (21): 2041.

https://doi.org/10.1182/blood.V120.21.2041.2041

Published: 2012

Journal Articles

The Role of Her2/Neu in ALL: Long Term Clinical Follow-up of Surface-Positive Patients and Induction of NK Cell ADCC by Trastuzumab in Vitro

Sebastian P. Haen, Benjamin J Schmiedel, PhD, Nora Roth, Christoph Faul, MD, Robert Möhle, Marc Schmalzing, MD, Lothar Kanz, MD, Wichard Vogel, MD, Helmut R Salih, MD

Blood (2012) 120 (21): 1421.

https://doi.org/10.1182/blood.V120.21.1421.1421

Published: 2012

Journal Articles

Development of New Autoimmunity Against T Cell Antigens Derived From Retinal Proteins After Allogeneic Hematopoietic Cell Transplantation.

Nora Roth, Christoph Faul, MD, Christiane Dorn, Wichard Vogel, MD, Wolfgang A. Bethge, MD, Lothar Kanz, MD, Hans-Georg Rammensee, Prof., Sebastian P. Haen

Blood (2012) 120 (21): 3060.

https://doi.org/10.1182/blood.V120.21.3060.3060

Published: 2012

Journal Articles

CD34 Selected Stem Cells Boosts Are Safe and Effective for Patients with Poor Bone Marrow Function After Allogeneic Hematopoietic Cell Transplantation.

Sebastian P. Haen, Michael Schumm, DVM, Christoph Faul, MD, Lothar Kanz, MD, Wolfgang A. Bethge, MD, Wichard Vogel, MD

Blood (2012) 120 (21): 3078.

https://doi.org/10.1182/blood.V120.21.3078.3078

Published: 2012

Journal Articles

Allogeneic Hematopoietic Cell Transplantation with FLAMSA-RIC Can Overcome the Poor Prognosis of Primary Refractory or Relapsed AML

Dominik Schneidawind, MD, Birgit Federmann, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang A. Bethge, MD

Blood (2011) 118 (21): 1938.

https://doi.org/10.1182/blood.V118.21.1938.1938

Published: 2011

Journal Articles

Results of Second or Third Allogeneic Hematopoietic Cell Transplantation As Salvage Therapy for Patients Failing Primary Transplantation

Birgit Federmann, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang A. Bethge, MD

Blood (2011) 118 (21): 4516.

https://doi.org/10.1182/blood.V118.21.4516.4516

Published: 2011

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Trial in progress: Phase II Study of (early) combination salvage therapy with venetoclax and intensified decitabine in relapsed/refractory AML (VenSwitch)

CD19/CD22 CAR-T cells in adult patients with relapsed/refractory B-cell malignancies

Trial in progress: Safety and feasibility of a venetoclax-augmented treosulfan-based reduced intensity conditioning before allogeneic stem cell transplantation in AML, MDS/AML and higher risk MDS (VeStAL)

Allogeneic Hematopoietic Cell Transplant Recipients Carrying DNMT3A and ASXL1 Mutations More Frequently Develop Severe Graft Versus Host Disease and Arterial Hypertension

Prospective Evaluation of Patient-Reported Outcome up to 10 Years after Allogeneic Stem Cell Transplantation Using FACT-G/BMT and EORTC-QLQ30 Questionnaires

Addition of Plerixafor Overcomes Poor Mobilization in Autologous and Allogeneic Stem Cell Grafts and Leads to Efficient and Sustained Engraftment

Disease and Therapy Associated Complications of the Central Nervous System after Allogeneic Hematopoietic Cell Transplantation - a Significant Proportion of Patients Will Suffer from Permanent Damage

Epigenetic Upregulation of the O-Linked Beta-N-Acetylglucosamine Transferase (OGT) in Response to Dronabinol Results in Antileukemic Efficacy In Vivo

Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome: Impact of Age and Conditioning

Haploidentical Transplantation As Salvage Therapy For Disease Relapse After Allogeneic Hematopoietic Cell Transplantation

Allogeneic Hematopoietic Cell Transplantation For Patients With Primary and Secondary Myelofibrosis: Report Of a Single Center Experience

Haploidentical TCRab Depleted Hematopoietic Cell Transplantation Leads To Rapid Immune Reconstitution and Promising Clinical Outcome In Adults

Central Nervous System Complications After Allogeneic Hematopoietic Cell Transplantation – Treatment Related Morbidity, Toxicity, Graft Versus Host Disease Or New Autoimmunity

Delayed Immune Reconstitution After Allogeneic Hematopoietic Cell Transplantation with Yttrium-90 Ibritumomab Tiuxetan-Based Reduced-Intensity Conditioning

Reduced-Intensity Conditioning with Fludarabine and Busulfan: Age Has No Negative Impact On Survival

The Role of Her2/Neu in ALL: Long Term Clinical Follow-up of Surface-Positive Patients and Induction of NK Cell ADCC by Trastuzumab in Vitro

Development of New Autoimmunity Against T Cell Antigens Derived From Retinal Proteins After Allogeneic Hematopoietic Cell Transplantation.

CD34 Selected Stem Cells Boosts Are Safe and Effective for Patients with Poor Bone Marrow Function After Allogeneic Hematopoietic Cell Transplantation.

Allogeneic Hematopoietic Cell Transplantation with FLAMSA-RIC Can Overcome the Poor Prognosis of Primary Refractory or Relapsed AML

Results of Second or Third Allogeneic Hematopoietic Cell Transplantation As Salvage Therapy for Patients Failing Primary Transplantation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only